Prabhat Singh | Pharmacology | Excellence in Research

Posted on by Forensic Scientist

Dr. Prabhat Singh | Neuroscience | Excellence in Research

Faculty of Pharmacy, Swami Vivekanand Subharti University | India

Dr. Prabhat Singh, a seasoned academic and researcher in the field of Pharmacology, currently serves as an Associate Professor at Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut. Born on July 8, 1988, Dr. Singh holds a B. Pharm., M. Pharm. (Pharmacology), and a Ph.D. His passion lies in advancing pharmaceutical education and scientific R&D. His academic dedication and research acumen have established him as a prominent figure in neuropharmacological research.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

Dr. Prabhat Singh demonstrates a consistent and impactful research trajectory in the field of Neuropharmacology, Vascular Dementia, and Physiological Brain Conditioning. With over 22 peer-reviewed publications, several in high-impact journals such as Neurochemical Research, Current Neurovascular Research, and Central Nervous System Agents in Medicinal Chemistry, his work reflects both depth and innovation.

  • He has published research with a total international impact factor exceeding 31.8, an h-index of 9, and over 300 citations, highlighting growing academic recognition.

  • His exploration of novel pharmacological targets in ischemia-reperfusion brain injury and morphine withdrawal syndromes represents translational value in therapeutic strategies.

  • Dr. Singh has contributed significantly to scholarly literature through book publications (4 authored books), book chapters (3 in Nova Science Publishers, USA), and 6 IPRs on innovative healthcare technologies, including AI-powered medication systems and neurodegenerative disease detection devices.

  • As a Ph.D. supervisor to six scholars and mentor to eight M.Pharm students, he has actively nurtured the next generation of pharmaceutical researchers.

🎓 Education

Dr. Singh completed his Ph.D. in Pharmacology from Dr. APJ Abdul Kalam Technical University, Lucknow in 2022. He earned his M. Pharm. from Mahamaya Technical University, Noida with an impressive 81.78% in 2013 and his B. Pharm. from Uttar Pradesh Technical University in 2011 with 73.19%. His foundational education was completed under the Uttar Pradesh Board, achieving consistent academic performance. He is also a GPAT qualifier (2011) and actively contributes to university committees.

👨‍🏫 Experience

Dr. Singh has over a decade of teaching experience. Since February 2023, he has been working as an Associate Professor at Kharvel Subharti College of Pharmacy. Previously, he served as Assistant Professor at the same institution from 2016 to 2023 and at Kalka Institute for Research and Advanced Studies from 2013 to 2016. Additionally, he has industrial experience as a Product Sales Representative with Dr. Reddy’s Laboratories. He has guided 08 M. Pharm theses and is currently supervising 06 Ph.D. scholars.

🔬 Research Interests On Pharmacology

Dr. Singh’s research interests are deeply rooted in Neuropharmacology, with specific focus on vascular dementia, neurotoxicity, and physiological brain conditioning. His doctoral research involved novel pharmacological interventions during experimental ischemia-reperfusion brain injury. His work integrates behavioral neuroscience and biochemical analysis to explore therapeutic pathways in brain disorders.

🏆 Awards & Achievements

Dr. Singh is a committed academic with a strong track record of publication and intellectual property. He has authored four books, contributed to multiple book chapters published by Nova Science Publishers, and published six IPRs including innovations in AI-based medication systems and neurodegenerative disease detection devices. His cumulative journal impact factor exceeds 31.8, with an h-index of 9 and over 300 citations.

đź“š Publications

  • Neuroprotective effects of agomelatine and vinpocetine against chronic cerebral hypoperfusion induced vascular dementia
    Authors: S Gupta, P Singh, B Mohan Sharma, B Sharma
    Year: 2015
    Citations: 73

  • Melatonin receptor and KATP channel modulation in experimental vascular dementia
    Authors: P Singh, S Gupta, B Sharma
    Year: 2015
    Citations: 45

  • Modulation of transient receptor potential vanilloid subtype 1 (TRPV1) and norepinephrine transporters (NET) protect against oxidative stress, cellular injury, and vascular …
    Authors: S Gupta, B Sharma, P Singh, B Mohan Sharma
    Year: 2014
    Citations: 40

  • Neuroprotective effects of nicorandil in chronic cerebral hypoperfusion-induced vascular dementia
    Authors: S Gupta, P Singh, B Sharma
    Year: 2016
    Citations: 26

  • Reversal in cognition impairments, cholinergic dysfunction, and cerebral oxidative stress through the modulation of ryanodine receptors (RyRs) and cysteinyl leukotriene-1 …
    Authors: P Singh, B Sharma
    Year: 2016
    Citations: 25

  • Selective serotonin-norepinephrine re-uptake inhibition limits renovascular-hypertension induced cognitive impairment, endothelial dysfunction, and oxidative stress injury
    Authors: P Singh, B Sharma
    Year: 2016
    Citations: 23

  • In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator
    Authors: P Singh, B Sharma, S Gupta, BM Sharma
    Year: 2015
    Citations: 22

  • Antiepileptic activity of aqueous extract of Tricosanthes dioica Roxb
    Authors: SG Prabhat Singh, Vipin K Garg, Pramod K Sharma
    Year: 2012
    Citations: 13

  • Plant bioactive compounds and their mechanistic approaches in the treatment of diabetes: a review
    Authors: Anshika, RK Pandey, L Singh, S Kumar, P Singh, M Pathak, S Jain
    Year: 2022
    Citations: 12

  • Antagonism of endothelin (ETA and ETB) receptors during renovascular hypertension-induced vascular dementia improves cognition
    Authors: P Singh, S Gupta, B Sharma
    Year: 2016
    Citations: 12

🧩 Conclusion

Dr. Prabhat Singh exemplifies academic excellence and research innovation in pharmacological sciences. With deep engagement in neuropharmacology, substantial teaching contributions, groundbreaking IPRs, and impactful publications, he continues to push the frontiers of pharmaceutical research and education. His commitment to scientific inquiry and student mentorship makes him a highly deserving candidate for this prestigious research award.

Mei-Lang Kung | Pharmacology | Women Researcher Award

Posted on by Forensic Scientist

Assist. Prof. Dr. Mei-Lang Kung | Pharmacology | Women Researcher Award

Senior Assistant Research Fellow | Kaohsiung Veterans General Hospital | Taiwan

Dr. Mei-Lang Kung is a distinguished researcher and academic specializing in cancer biology, gene engineering, and phytochemical pharmacology. She currently serves as a Senior Assistant Research Fellow at the Department of Medical Education and Research, Kaohsiung Veterans General Hospital, and an Assistant Professor at Shu-Zen Junior College of Medicine and Management. With a strong background in molecular biology and nanomedicine, Dr. Kung has contributed significantly to innovative research in oncology and nanomaterials for medical applications.

Profile👤

ORCID

Scopus

Strengths for the Awards✨

  • Strong Academic Background đź“š

    • Dr. Mei-Lang Kung holds a Ph.D. in Biological Science from National Sun Yat-sen University (2012).
    • Her dissertation focused on cancer cell migration and epithelial-mesenchymal transition, a highly relevant area in biomedical research.

  • Extensive Research Expertise 🔬

    • Her work spans multiple interdisciplinary fields, including cancer biology, gene engineering, phytochemical pharmacology, and green nanomaterials.
    • These diverse skill sets enhance the impact of her research in translational medicine.

  • Significant Research Contributions 🏆

    • 21+ peer-reviewed publications in high-impact journals (SCI-indexed).
    • Notable research on nanomedicine and cancer treatment strategies, contributing to innovative therapeutic approaches.
    • Demonstrated leadership as a corresponding author in multiple studies, reflecting independent research capability.

  • Recognition & Awards 🥇

    • Best Poster Award (2021) from the Taiwan Urology Association.
    • National Taiwan University System Young Scholars Award (2018) for innovative research.
    • Multiple Outstanding Paper Awards at prestigious conferences (IEEE, New Advance in Medicine, etc.).
    • These accolades highlight her excellence in research and scholarly impact.

Education 🎓

Dr. Kung earned her Ph.D. in Biological Science from National Sun Yat-sen University, Kaohsiung, Taiwan, in 2012, under the guidance of Prof. Tai Ming-Hong. Her dissertation focused on the mechanisms of hepatoma-derived growth factor-mediated cell migration and epithelial-mesenchymal transition. She also holds an M.S. in Biochemistry from Kaohsiung Medical University (2002) and a B.S. in Nutrition from Chung Shan Medical University (2000).

Experience 🌟

Dr. Kung has extensive experience in academia and research. Since 2019, she has been a Senior Assistant Research Fellow at Kaohsiung Veterans General Hospital. She also holds a faculty position at Shu-Zen Junior College of Medicine and Management. Previously, she served as an Assistant Faculty member (2017-2019) and a Postdoctoral Research Associate (2012-2017) in the Chemistry Department of National Sun Yat-sen University, working under Dr. Shuchen Hsieh.

Research Interests On Pharmacology đź“š

Dr. Kung’s research interests include cancer biology, gene engineering, phytochemical pharmacology, and toxicology. She is particularly focused on the development and applications of green nanomaterials for cancer treatment. Her work explores novel phytochemically derived nanoparticles and their effects on cancer cell adhesion, proliferation, and metastasis.

Awards 🏆

  • 2021: Taiwan Urology Association “Best Academic Activity Award – Best Poster Award”
  • 2018: National Taiwan University System Young Scholars Selection for Innovative Research and Development Achievements – Excellent Work Award
  • 2015: New Advance in Generation Medicine, Cancer and Stem Cell Outstanding Paper Award
  • 2013: IEEE Nanotechnology Materials and Devices Conference, Outstanding Paper Award

Publications đź“°

Dr. Kung has authored numerous peer-reviewed publications in high-impact journals. Below are some of her notable works:

  1. Wang, J.-H., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2025). “Nanosized ginger-derived phenolic zingerone obstructs cell cycle G2/M progression and initiates apoptosis in human colorectal cancer.” Environmental Toxicology. DOI:10.1002/tox.24470 (SCI; 2023 IF=4.4)
  2. Chu, L.-W., Chen, J.-Y., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2024). “Phytoconstituent-derived zingerone nanoparticles disrupt cell adhesion and suppress cell motility in melanoma B16F10 cells.” Journal of Biotechnology. DOI:10.1016/j.jbiotec.2024.06.015
  3. Kung, M.-L., Cheng, S. M., Wang, Y.-H., et al.* (2024). “Deficiency of RNA adenosine deaminase (ADAR2) ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in male diet-induced obese mice.” Communications Biology. (SCI; 2022 IF=5.9)
  4. Kung, M.-L., Yang, T.-H., Lin, C.-C., et al.* (2024). “ADAR2 deficiency ameliorates nonalcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.” Journal of Cachexia, Sarcopenia and Muscle. DOI:10.1002/jcsm.13460 (SCI; 2022 IF=8.9)
  5. Hu, T.-H., Wu, J.-C., Huang, S.-T., et al.* (2023). “HDGF Stimulates Liver Tumorigenesis by Enhancing Reactive Oxygen Species Generation in Mitochondria.” Journal of Biological Chemistry. (SCI; 2022 IF=4.8)

Conclusion đź“š

Dr. Mei-Lang Kung has made remarkable contributions to cancer research and nanomedicine, with a strong emphasis on translating scientific discoveries into therapeutic applications. Her expertise in molecular oncology and green nanotechnology continues to impact the scientific community, making her a leader in the field of biomedical research. Through her innovative work, she strives to advance cancer treatment strategies and improve patient outcomes.